nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

30.03.2016 | Original Article

Early [¹⁸F]florbetaben and [¹¹C]PiB PET images are a surrogate biomarker of neuronal injury in Alzheimer’s disease

verfasst von: Solveig Tiepolt, Swen Hesse, Marianne Patt, Julia Luthardt, Matthias L. Schroeter, Karl-Titus Hoffmann, David Weise, Hermann-Josef Gertz, Osama Sabri, Henryk Barthel

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 9/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

[¹⁸F]FDG is a commonly used neuronal injury biomarker for early and differential diagnosis of dementia. Typically, the blood supply to the brain is closely coupled to glucose consumption. Early uptake of the Aβ tracer [¹¹C]PiB on PET images is mainly determined by cerebral blood flow and shows a high correlation with [¹⁸F]FDG uptake. Uptake data for ¹⁸F-labelled Aβ PET tracers are, however, scarce. We investigated the value of early PET images using the novel Aβ tracer [¹⁸F]FBB in the diagnosis of Alzhimers disease (AD).

Methods

This retrospective analysis included 22 patients with MCI or dementia who underwent dual time-point PET imaging with either [¹¹C]PiB (11 patients) or [¹⁸F]FBB (11 patients) in routine clinical practice. Images were acquired 1 – 9 min after administration of both tracers and 40 – 70 min and 90 – 110 min after administration of [¹¹C]PiB and [¹⁸F]FBB, respectively. The patients also underwent [¹⁸F]FDG brain PET imaging. PET data were analysed visually and semiquantitatively. Associations between early Aβ tracer uptake and dementia as well as brain atrophy were investigated.

Results

Regional visual scores of early Aβ tracer and [¹⁸F]FDG PET images were significantly correlated (Spearman’s ρ = 0.780, P < 0.001). Global brain visual analysis revealed identical results between early Aβ tracer and [¹⁸F]FDG PET images. In a VOI-based analysis, the early Aβ tracer data correlated significantly with the [¹⁸F]FDG data (r = 0.779, P < 0.001), but there were no differences between [¹⁸F]FBB and [¹¹C]PiB. Cortical SUVRs in regions typically affected in AD on early Aβ tracer and [¹⁸F]FDG PET images were correlated with MMSE scores (ρ = 0.458, P = 0.032, and ρ = 0.456, P = 0.033, respectively). A voxel-wise group-based search for areas with relatively higher tracer uptake on early Aβ tracer PET images compared with [¹⁸F]FDG PET images revealed a small cluster in the midbrain/pons; no significant clusters were found for the opposite comparison.

Conclusion

Early [¹⁸F]FBB and [¹¹C]PiB PET brain images are similar to [¹⁸F]FDG PET images in AD patients, and these tracers could potentially be used as biomarkers in place of [¹⁸F]FDG. Thus, Aβ tracer PET imaging has the potential to provide biomarker information on AD pathology and neuronal injury. The potential of this approach for supporting the diagnosis of AD needs to be confirmed in prospective studies in larger cohorts.

McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):263–9.CrossRefPubMedPubMedCentral

Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol. 2014;13(6):614–29.CrossRefPubMed

Tiepolt S, Barthel H, Butzke D, Hesse S, Patt M, Gertz H, et al. Influence of scan duration on the accuracy of β-amyloid PET with florbetaben in patients with Alzheimer’s disease and healthy volunteers. Eur J Nucl Med Mol Imaging. 2013;40(2):238–44.CrossRefPubMed

Barthel H, Seibyl J, Sabri O. The role of positron emission tomography imaging in understanding Alzheimer’s disease [ENG]. Expert review of neurotherapeutics. Expert Rev Neurother. 2015;15(4):395–406.CrossRefPubMed

Schroeter ML, Neumann J. Combined imaging markers dissociate Alzheimer’s disease and frontotemporal lobar degeneration – an ALE meta-analysis. Front Aging Neurosci. 2011;3:10. doi:10.3389/fnagi.2011.00010.CrossRefPubMedPubMedCentral

Schroeter ML, Stein T, Maslowski N, Neumann J. Neural correlates of Alzheimer’s disease and mild cognitive impairment: a systematic and quantitative meta-analysis involving 1351 patients. Neuroimage. 2009;47(4):1196–206. doi:10.1016/j.neuroimage.2009.05.037.CrossRefPubMedPubMedCentral

Meyer PT, Hellwig S, Amtage F, Rottenburger C, Sahm U, Reuland P, et al. Dual-biomarker imaging of regional cerebral amyloid load and neuronal activity in dementia with PET and 11C-labeled Pittsburgh compound B. J Nucl Med. 2011;52(3):393–400.CrossRefPubMed

Becker GA, Ichise M, Barthel H, Luthardt J, Patt M, Seese A, et al. PET quantification of 18F-florbetaben binding to β-amyloid deposits in human brains. J Nucl Med. 2013;54(5):723–31.CrossRefPubMed

Rostomian AH, Madison C, Rabinovici GD, Jagust WJ. Early 11C-PIB frames and 18F-FDG PET measures are comparable: a study validated in a cohort of AD and FTLD patients. J Nucl Med. 2011;52(2):173–9.PubMedPubMedCentral

10.

Forsberg A, Engler H, Blomquist G, Långström B, Nordberg A. The use of PIB-PET as a dual pathological and functional biomarker in AD. Biochim Biophys Acta. 2012;1822(3):380–5.CrossRefPubMed

11.

Hsiao I, Huang C, Hsieh C, Hsu W, Wey S, Yen T, et al. Correlation of early-phase 18F-florbetapir (AV-45/Amyvid) PET images to FDG images: preliminary studies. Eur J Nucl Med Mol Imaging. 2012;39(4):613–20.CrossRefPubMed

12.

McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology. 1984;34(7):939–44.CrossRefPubMed

13.

Werner P, Barthel H, Drzezga A, Sabri O. Current status and future role of brain PET/MRI in clinical and research settings. Eur J Nucl Med Mol Imaging. 2015;42(3):512–26.CrossRefPubMed

14.

Barthel H, Gertz H, Dresel S, Peters O, Bartenstein P, Buerger K, et al. Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer’s disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol. 2011;10(5):424–35.CrossRefPubMed

15.

Price JC, Klunk WE, Lopresti BJ, Lu X, Hoge JA, Ziolko SK, et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab. 2005;25(11):1528–47.CrossRefPubMed

16.

Suotunen T, Hirvonen J, Immonen-Räihä P, Aalto S, Lisinen I, Arponen E, et al. Visual assessment of [(11)C]PIB PET in patients with cognitive impairment. Eur J Nucl Med Mol Imaging. 2010;37(6):1141–7.CrossRefPubMed

17.

Barthel H, Luthardt J, Becker G, Patt M, Hammerstein E, Hartwig K, et al. Individualized quantification of brain β-amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer’s disease and healthy controls. Eur J Nucl Med Mol Imaging. 2011;38(9):1702–14.CrossRefPubMed

18.

Sabri O, Sabbagh MN, Seibyl J, Barthel H, Akatsu H, Ouchi Y, et al. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer disease: phase 3 study. Alzheimers Dement. 2015;11(8):964–74. doi:10.1016/j.jalz.2015.02.004.

19.

Schroeter ML, Raczka K, Neumann J, von Cramon DY. Neural networks in frontotemporal dementia – a meta-analysis. Neurobiol Aging. 2008;29(3):418–26. doi:10.1016/j.neurobiolaging.2006.10.023.CrossRefPubMed

20.

Dukart J, Mueller K, Horstmann A, Vogt B, Frisch S, Barthel H, et al. Differential effects of global and cerebellar normalization on detection and differentiation of dementia in FDG-PET studies. Neuroimage. 2010;49(2):1490–5. doi:10.1016/j.neuroimage.2009.09.017.CrossRefPubMed

21.

Villemagne VL, Mulligan RS, Pejoska S, Ong K, Jones G, O’Keefe G, et al. Comparison of 11C-PiB and 18F-florbetaben for Aβ imaging in ageing and Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2012;39(6):983–9.CrossRefPubMed

22.

Scheltens P, Leys D, Barkhof F, Huglo D, Weinstein HC, Vermersch P, et al. Atrophy of medial temporal lobes on MRI in “probable” Alzheimer’s disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry. 1992;55(10):967–72.CrossRefPubMedPubMedCentral

23.

Blomquist G, Engler H, Nordberg A, Ringheim A, Wall A, Forsberg A, et al. Unidirectional Influx and net accumulation of PIB. Open Neuroimag J. 2008;2:114–25.CrossRefPubMedPubMedCentral

24.

Jack CR, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, et al. Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol. 2010;9(1):119–28. doi:10.1016/S1474-4422(09)70299-6.CrossRefPubMedPubMedCentral

25.

Arlt S, Brassen S, Jahn H, Wilke F, Eichenlaub M, Apostolova I, et al. Association between FDG uptake, CSF biomarkers and cognitive performance in patients with probable Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2009;36(7):1090–100.CrossRefPubMed

26.

Kadir A, Almkvist O, Forsberg A, Wall A, Engler H, Långström B, et al. Dynamic changes in PET amyloid and FDG imaging at different stages of Alzheimer’s disease. Neurobiol Aging. 2012;33(1):98.e1–14.

27.

Johnson KA, Minoshima S, Bohnen NI, Donohoe KJ, Foster NL, Herscovitch P, et al. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. J Nucl Med. 2013;54:476–90.CrossRefPubMed

28.

Booij J, Arbizu J, Darcourt J, Hesse S, Nobili F, Payoux P, et al. Appropriate use criteria for amyloid PET imaging cannot replace guidelines: on behalf of the European Association of Nuclear Medicine. Eur J Nucl Med Mol Imaging. 2013;40(7):1122–5.CrossRefPubMed

Titel: Early [18F]florbetaben and [11C]PiB PET images are a surrogate biomarker of neuronal injury in Alzheimer’s disease
verfasst von: Solveig Tiepolt
Swen Hesse
Marianne Patt
Julia Luthardt
Matthias L. Schroeter
Karl-Titus Hoffmann
David Weise
Hermann-Josef Gertz
Osama Sabri
Henryk Barthel
Publikationsdatum: 30.03.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 9/2016
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-016-3353-1

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2016

Role of 68Ga somatostatin receptor PET/CT in the detection of endogenous hyperinsulinaemic focus: an explorative study

Is 18FDG uptake useful to decide on chemotherapy in ER+/HER2- breast cancer?

Erratum to: Dual-phase amyloid PET: hitting two birds with one stone

Radiation dosimetry of 68Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing

William T. O’Brien Sr. (Ed.), Top 3 Differentials in Neuroradiology: A Case Review. Thieme Medical Publishers, Inc., 2015. ISBN 978-1- 60406-723-1

Direct comparison of 68Ga-DOTA-TOC and 18F-FDG PET/CT in the follow-up of patients with neuroendocrine tumour treated with the first full peptide receptor radionuclide therapy cycle